Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Xya02

Preclinical

XXYone Therapeutics, Inc

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Refractory Solid TumorsNot yet recruiting

Refractory Solid TumorsPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q3 2030

PreclinicalNot yet recruiting

Refractory Solid Tumors

NCT07670312

Clinical

Trials by Indication[1]

Refractory Solid Tumors1 trial

A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors

Not yet recruiting·XXYone Therapeutics, Inc·Preclinical·NCT07670312·190 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Xya02. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Xya02. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — XYone Therapeutics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: XXYone Therapeutics, Inc

Related News